Cargando…

How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research

SIMPLE SUMMARY: This commentary reflects a collaborative effort between international Invasive Lobular Carcinoma (ILC)-focused breast cancer researchers, clinicians and patient advocate leaders. It offers a perspective on the progress made in ILC research in recent years and discusses the recent ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Pate, Leigh, Desmedt, Christine, Metzger, Otto, Burgess Hutcheson, Laurie, Turner, Claire, Freeney, Siobhán, Oesterreich, Steffi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268486/
https://www.ncbi.nlm.nih.gov/pubmed/34206261
http://dx.doi.org/10.3390/cancers13133094
_version_ 1783720368939204608
author Pate, Leigh
Desmedt, Christine
Metzger, Otto
Burgess Hutcheson, Laurie
Turner, Claire
Freeney, Siobhán
Oesterreich, Steffi
author_facet Pate, Leigh
Desmedt, Christine
Metzger, Otto
Burgess Hutcheson, Laurie
Turner, Claire
Freeney, Siobhán
Oesterreich, Steffi
author_sort Pate, Leigh
collection PubMed
description SIMPLE SUMMARY: This commentary reflects a collaborative effort between international Invasive Lobular Carcinoma (ILC)-focused breast cancer researchers, clinicians and patient advocate leaders. It offers a perspective on the progress made in ILC research in recent years and discusses the recent rise in patient advocate involvement to advance ILC research, raise awareness and educate about this disease. It outlines several distinct challenges in conducting ILC research and describes opportunities and suggestions for ways researchers, clinicians and advocates can work together to advance ILC research to develop new therapies and refine the care offered to patients. ABSTRACT: Breast cancer research and therapies have significantly advanced in recent years. However, Invasive Lobular Carcinoma (ILC), the second most common histological type of breast cancer and the sixth most frequently diagnosed cancer of women, has not always benefited from critical analysis, missing opportunities to better understand this important subtype. Recent progress understanding the biological and behavioral differences of ILC demonstrates that it is a unique subtype of breast cancer which can respond differently to common therapies. These new insights have increased interest in researching lobular breast disease. Concurrently, the formation of motivated patient-led advocacy organizations working in partnership with basic, translational and clinical researchers creates new opportunities, including connecting a dispersed patient population to research, encouraging new research funding and connecting patient advocates to researchers to advance common goals. This commentary will explore the unprecedented opportunity to drive multidisciplinary, multicenter and international collaborative research into lobular breast cancer that builds on recent research progress. Collaborative research partnerships that include advocates can result in a better understanding of ILC, identify targeted therapies and refine standard of care therapies that are currently equally applied to all breast cancers, resulting in improvements in the diagnosis, treatment and follow-up care for patients with ILC.
format Online
Article
Text
id pubmed-8268486
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82684862021-07-10 How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research Pate, Leigh Desmedt, Christine Metzger, Otto Burgess Hutcheson, Laurie Turner, Claire Freeney, Siobhán Oesterreich, Steffi Cancers (Basel) Commentary SIMPLE SUMMARY: This commentary reflects a collaborative effort between international Invasive Lobular Carcinoma (ILC)-focused breast cancer researchers, clinicians and patient advocate leaders. It offers a perspective on the progress made in ILC research in recent years and discusses the recent rise in patient advocate involvement to advance ILC research, raise awareness and educate about this disease. It outlines several distinct challenges in conducting ILC research and describes opportunities and suggestions for ways researchers, clinicians and advocates can work together to advance ILC research to develop new therapies and refine the care offered to patients. ABSTRACT: Breast cancer research and therapies have significantly advanced in recent years. However, Invasive Lobular Carcinoma (ILC), the second most common histological type of breast cancer and the sixth most frequently diagnosed cancer of women, has not always benefited from critical analysis, missing opportunities to better understand this important subtype. Recent progress understanding the biological and behavioral differences of ILC demonstrates that it is a unique subtype of breast cancer which can respond differently to common therapies. These new insights have increased interest in researching lobular breast disease. Concurrently, the formation of motivated patient-led advocacy organizations working in partnership with basic, translational and clinical researchers creates new opportunities, including connecting a dispersed patient population to research, encouraging new research funding and connecting patient advocates to researchers to advance common goals. This commentary will explore the unprecedented opportunity to drive multidisciplinary, multicenter and international collaborative research into lobular breast cancer that builds on recent research progress. Collaborative research partnerships that include advocates can result in a better understanding of ILC, identify targeted therapies and refine standard of care therapies that are currently equally applied to all breast cancers, resulting in improvements in the diagnosis, treatment and follow-up care for patients with ILC. MDPI 2021-06-22 /pmc/articles/PMC8268486/ /pubmed/34206261 http://dx.doi.org/10.3390/cancers13133094 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Pate, Leigh
Desmedt, Christine
Metzger, Otto
Burgess Hutcheson, Laurie
Turner, Claire
Freeney, Siobhán
Oesterreich, Steffi
How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research
title How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research
title_full How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research
title_fullStr How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research
title_full_unstemmed How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research
title_short How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research
title_sort how researchers, clinicians and patient advocates can accelerate lobular breast cancer research
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268486/
https://www.ncbi.nlm.nih.gov/pubmed/34206261
http://dx.doi.org/10.3390/cancers13133094
work_keys_str_mv AT pateleigh howresearcherscliniciansandpatientadvocatescanacceleratelobularbreastcancerresearch
AT desmedtchristine howresearcherscliniciansandpatientadvocatescanacceleratelobularbreastcancerresearch
AT metzgerotto howresearcherscliniciansandpatientadvocatescanacceleratelobularbreastcancerresearch
AT burgesshutchesonlaurie howresearcherscliniciansandpatientadvocatescanacceleratelobularbreastcancerresearch
AT turnerclaire howresearcherscliniciansandpatientadvocatescanacceleratelobularbreastcancerresearch
AT freeneysiobhan howresearcherscliniciansandpatientadvocatescanacceleratelobularbreastcancerresearch
AT oesterreichsteffi howresearcherscliniciansandpatientadvocatescanacceleratelobularbreastcancerresearch